Abstract

目的分析CD20阳性多发性骨髓瘤(MM)患者的临床和实验室检查特征。方法回顾性分析62例CD20阳性初诊MM患者的临床及实验室检查资料,并与CD20阴性患者进行比较。结果①采用流式细胞术进行CD20分析的465例初诊MM患者中,CD20阳性者62例(13.3%)。②CD20阳性与阴性组患者比较,其性别、年龄、Durie-Salmon分期、ISS分期、肾功能损害、LDH水平、血小板计数及免疫球蛋白类型差异均无统计学意义(P值均>0.05)。③CD20阳性组患者血红蛋白水平(74.5 g/L对83.5 g/L,P=0.021)、髓外浸润发生率(3.5%对13.7%,P=0.029)、CD56阳性细胞率(36.7%对68.8%,P=0.000)、t(4;14)发生率(2.4%对24.0%,P=0.001)明显低于CD20阴性组。④CD20阳性组患者骨髓浆细胞比例(0.400对0.295,P=0.045)及恶性浆细胞比例(20.0%对6.8%,P=0.000)、CD45阳性细胞率(12.1%对4.5%,P=0.018)、CD79a阳性细胞率(9.8%对1.5%,P=0.013)、t(11;14)发生率(60.5%对14.4%,P=0.000)明显高于CD20阴性组。⑤两组患者对治疗的反应率、完全缓解率、无进展生存及总体生存时间差异均无统计学意义(P值均>0.05)。结论MM患者CD20阳性发生率为13.3%,CD20阳性MM患者的瘤细胞更易在骨髓浸润,累及红系造血,免疫表型更多为不典型表现。与CD20阴性患者比较,CD20阳性患者t(11;14)发生率明显升高,而t(4;14)发生率明显降低。

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.